Private Advisor Group LLC raised its position in shares of iShares Biotechnology ETF (NASDAQ:IBB – Free Report) by 3.6% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 48,363 shares of the financial services provider’s stock after buying an additional 1,683 shares during the quarter. Private Advisor Group LLC’s holdings in iShares Biotechnology ETF were worth $6,160,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. WealthPLAN Partners LLC bought a new position in shares of iShares Biotechnology ETF during the first quarter valued at $27,000. CoreFirst Bank & Trust bought a new position in shares of iShares Biotechnology ETF during the second quarter valued at $30,000. Archer Investment Corp bought a new position in shares of iShares Biotechnology ETF during the second quarter valued at $48,000. Newbridge Financial Services Group Inc. increased its holdings in shares of iShares Biotechnology ETF by 27.6% during the second quarter. Newbridge Financial Services Group Inc. now owns 388 shares of the financial services provider’s stock valued at $49,000 after acquiring an additional 84 shares in the last quarter. Finally, Crewe Advisors LLC bought a new position in shares of iShares Biotechnology ETF during the first quarter valued at $51,000. Hedge funds and other institutional investors own 69.61% of the company’s stock.
iShares Biotechnology ETF Stock Performance
Shares of NASDAQ:IBB opened at $118.10 on Friday. iShares Biotechnology ETF has a 1-year low of $111.83 and a 1-year high of $138.74. The business has a fifty day moving average price of $120.30 and a 200-day moving average price of $125.63.
iShares Biotechnology ETF Dividend Announcement
About iShares Biotechnology ETF
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.
- Five stocks we like better than iShares Biotechnology ETF
- Low PE Growth Stocks: Unlocking Investment Opportunities
- MarketBeat Week in Review – 11/13 – 11/17
- What is a Death Cross in Stocks?
- 3 large caps with red hot RSIs with upside
- How to Use Stock Screeners to Find Stocks
- Johnson Controls International: Nothing but upside for investors
Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.